Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Receivables - Net: 2010-2024

Historic Receivables - Net for Vanda Pharmaceuticals (VNDA) over the last 15 years, with Dec 2024 value amounting to $47.1 million.

  • Vanda Pharmaceuticals' Receivables - Net rose 18.22% to $50.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $50.5 million, marking a year-over-year increase of 18.22%. This contributed to the annual value of $47.1 million for FY2024, which is 37.90% up from last year.
  • Latest data reveals that Vanda Pharmaceuticals reported Receivables - Net of $47.1 million as of FY2024, which was up 37.90% from $34.2 million recorded in FY2023.
  • In the past 5 years, Vanda Pharmaceuticals' Receivables - Net registered a high of $47.1 million during FY2024, and its lowest value of $30.0 million during FY2020.
  • Its 3-year average for Receivables - Net is $38.3 million, with a median of $34.2 million in 2023.
  • Data for Vanda Pharmaceuticals' Receivables - Net shows a peak YoY skyrocketed of 37.90% (in 2024) over the last 5 years.
  • Yearly analysis of 5 years shows Vanda Pharmaceuticals' Receivables - Net stood at $30.0 million in 2020, then rose by 8.09% to $32.5 million in 2021, then increased by 3.22% to $33.5 million in 2022, then increased by 1.92% to $34.2 million in 2023, then spiked by 37.90% to $47.1 million in 2024.